#radonc #lcsm #sclc **Optimizing Radiotherapy for LS-SCLC: The Superiority of Twice-Daily (BID) Dosing and the Shift Toward Dose Escalation** 🧬💊 Recent evidence is reshaping the treatment landscape for Limited-Stage Small Cell Lung Cancer (LS-SCLC). A comprehensive real-world study from the Netherlands (Bosch et al.) highlights a critical divide in treatment efficacy based on patient age and fractionation schedules 📊 **The Real-World Evidence: BID vs. OD** In patients under 70 years old, twice-daily (BID) radiotherapy—typically 45 Gy in 30 fractions—demonstrated a clear survival advantage over once-daily (OD) schedules . ✅ **Survival:** Younger patients treated with BID achieved a median overall survival of **36.0 months**, compared to only **22.2 months** for those on OD schedules ✅ **Safety:** Importantly, the BID regimen did not increase severe 90-day acute toxicity in this younger cohort, making it both more effective and equally safe 👴 **The Age Factor (70+ Years)** For patients aged 70 and older, the data shows a different trend. There was no significant difference in survival between BID (21.8 months) and OD (24.3 months) Furthermore, older patients treated with BID showed numerically higher toxicity levels . This suggests that for elderly or frailer patients, treatment must be highly individualized . 🚀 **The New Frontier: Dose Escalation** While 45 Gy BID has long been the standard, the study highlights that increasing the dose further can lead to even more remarkable outcomes for "fit" patients: 🔹 **54 Gy BID:** Recent Phase 3 trials (Yu et al.) reported an unprecedented median survival of **60.7 months** 🔹 **60 Gy BID:** Phase 2 data (Grønberg et al.) showed a median survival of **37.2 months** compared to 22.6 months with the standard dose. 💡 **Clinical Takeaway** For younger patients with good performance status, **twice-daily radiotherapy is the superior choice**, and **dose escalation** (moving beyond 45 Gy) represents the next logical step to maximize long-term survival

#psm Guidelines !